- Active not recruitingPHASE2
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
This study looks at giving olaparib, a new drug, before surgery and chemotherapy for recurrent ovarian, primary peritoneal, or fallopian tube cancer. It aims to see if it can shrink tumours and improve outcomes.
For: Ovarian Cancer · Fallopian Tube Cancer · Neoadjuvant TreatmentCanada · New Zealand · Spain - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
For: Solid Tumors · Hematologic MalignanciesUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study is testing a new use for olaparib, a medicine to treat advanced cancers that have specific gene changes. It's for people whose cancer hasn't responded to usual treatments and has gene faults linked to how cells repair themselves.
For: Advanced Solid NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
For: Breast CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This study is testing a new drug, ART6043, alone or with an existing drug, olaparib, for people with advanced or metastatic solid tumours. Researchers want to see if it's safe, how it works in the body, and if it helps treat these cancers, especially those with certain genetic changes.
For: Advanced Solid Tumor · Metastatic Solid TumorUnited States · Spain · United Kingdom - Active not recruitingPHASE2
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This study looks at new drug combinations for certain advanced cancers. It aims to understand how these drugs affect cancer at a genetic level and in the body. It combines an immunotherapy drug with another type of cancer drug.
For: Mismatch Repair Proficient Colorectal Cancer · Pancreatic Adenocarcinoma · LeiomyosarcomaCanada - RecruitingEARLY_PHASE1
Pilot Trial for Treatment of Recurrent Glioblastoma
This early trial aims to test new, personalised treatments for people with an aggressive type of brain tumour called glioblastoma that has come back. It will check if these treatments are safe and if this type of study can be done on a larger scale.
For: Glioblastoma · Recurrent Disease · Recurrent GlioblastomaCanada - Active not recruitingPHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery and where standard chemotherapy isn't an option. It tests two drugs, Durvalumab and Olaparib, to see if they are safe and effective.
For: Urinary Bladder NeoplasmsUnited States · Canada · Russia - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE1
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
This study is for people with bladder cancer that's spread and hasn't responded to previous treatment. It tests several new drug treatments, alone or in combination, to see if they're safe and effective. Doctors will check your tumour for specific changes to decide which treatment might be best for you.
For: Muscle Invasive Bladder CancerUnited States · Canada · France - Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance - RecruitingPHASE1, PHASE2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
This study is for children and young people with cancer that hasn't responded to usual treatments. It tests new medicines that target specific changes in cancer cells, aiming to find the right dose and see if they help. The goal is to find better ways to treat childhood cancer.
For: Pediatric CancerDenmark · France · Italy - Active not recruitingPHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
This study looks at a new combination treatment for advanced prostate cancer that has spread. It compares olaparib plus abiraterone with abiraterone alone to see if the new combination works better and is safe for men who haven't had previous strong treatments.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
This study is looking at a new way to treat advanced ovarian cancer. It combines a drug called olaparib with standard chemotherapy (carboplatin and paclitaxel) to see if it works better and is safe compared to chemotherapy alone.
For: Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE2
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
This study is testing a new combination of two drugs, pembrolizumab and olaparib, for people with pancreatic cancer that has spread. It focuses on patients whose cancer has specific genetic changes, hoping to find a more effective treatment.
For: Pancreatic CancerAustralia · United Kingdom - Active not recruitingPHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This study is testing different combinations of new drugs (olaparib, durvalumab, capivasertib, and cediranib) for recurrent or hard-to-treat womb cancer. The aim is to find out if these combinations can stop the cancer from growing or spreading more effectively.
For: Endometrial Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous AdenocarcinomaUnited States · Canada - RecruitingPHASE2
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
This study looks at adding a drug called elacestrant to olaparib for patients with a certain type of advanced breast cancer and a BRCA gene change. It hopes to see if this combination works better than olaparib alone.
For: Hormone Receptor Positive HER-2 Negative Breast Cancer · Advanced or Metastatic Breast Cancer · BRCA1 MutationGermany - Active not recruitingPHASE2
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
This study looks at whether adding a drug called olaparib to standard radiation therapy helps women with inflammatory breast cancer. Olaparib aims to stop cancer cells from repairing themselves. Researchers want to see if this combination improves recovery and survival.
For: Breast Inflammatory CarcinomaUnited States · Canada · Puerto Rico - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
For: Ovarian Cancer · Breast CancerUnited States · Belgium · Bulgaria - Active not recruitingPHASE2
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
This study is looking at a new combination treatment, olaparib and pembrolizumab, for adults with advanced cancers. It focuses on specific types of solid tumours that have certain genetic changes or deficiencies in how their cells repair themselves.
For: Solid TumorsUnited States · Argentina · Australia - Active not recruitingPHASE3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
This study is looking into new ways to treat advanced or recurrent womb cancer. We're testing a combination of medicines called durvalumab and olaparib, given after initial chemotherapy, to see if they can help patients live longer and better.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This study is for people with certain types of breast cancer to see if adding a drug called olaparib to standard chemotherapy before surgery can improve treatment. It's focused on triple-negative breast cancer or breast cancer linked to a BRCA gene change.
For: Breast CancerUnited Kingdom - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.
For: Ovarian CancerUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
This study is testing new treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see how safe and effective a new drug, Opevesostat, is when given alone or with other medicines to men with this condition.
For: Prostatic Neoplasms, Castration-ResistantUnited States · Australia · Canada - Active not recruitingPHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
This study looks at new treatments for gynaecological cancers that have come back. It tests a drug called ceralasertib, sometimes with olaparib or durvalumab, to see how well they work in different types of cancer cells, especially those with a specific gene change called ARID1A loss.
For: Gynaecological CancersCanada · United Kingdom - RecruitingPHASE2, PHASE3
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
This study looks at new treatments for endometrial cancer based on specific cancer features. It aims to find better ways to treat patients after surgery, potentially leading to personalised care for different types of endometrial cancer.
For: Endometrial CancerCanada · France · Netherlands - RecruitingPHASE1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.
For: Advanced Solid Tumor · Metastatic Solid Tumor · Prostate CancerUnited States · Spain · United Kingdom - Active not recruitingPHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This study looks at new ways to treat advanced non-small cell lung cancer that hasn't spread after initial treatment. It compares two treatments: Durvalumab alone, and Durvalumab combined with Olaparib, to see if the combination helps patients live longer and better.
For: Non-small Cell Lung Cancer NSCLCUnited States · Belgium · Hungary - Active not recruitingPHASE1, PHASE2
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
This study is looking at new drug combinations for advanced cancers like ovarian, breast, lung, and stomach cancer. It checks how safe and effective they are, and how they work in the body.
For: Ovarian · Breast · SCLCUnited States · France · Israel - Active not recruitingPHASE3
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
This study looks at new ways to treat advanced lung cancer that can't be removed by surgery. It combines standard chemotherapy and radiation with newer drugs, pembrolizumab and olaparib, to see if they can improve survival compared to current treatments.
For: Lung Neoplasms · Carcinoma, Non-Small-Cell LungUnited States · Argentina · Canada - RecruitingPHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
This study looks at new treatments for triple negative breast cancer that hasn't fully responded to initial chemotherapy. We're testing if medicines, given briefly before surgery, can start to shrink the cancer or change it in helpful ways.
For: Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRDUnited Kingdom - Active not recruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
For: Solid TumorsUnited States · France · Italy - RecruitingPHASE2
WIRE - Novel Treatments in Renal Cell Cancer
This study looks at new medicines for kidney cancer that can be removed by surgery. Patients take a medicine for a short time before their operation. We want to see how these medicines affect the cancer and the body, to find better ways to treat this type of kidney cancer.
For: Renal Cell CancerUnited Kingdom